Global airway disease: mepolizumab simultaneously improves outcomes in severe CRSwNP and asthma

Chronic rhinosinusitis with nasal polyps (CRSwNP) often co-exists with asthma and non-steroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD), creating a more severe phenotype and an additional burden compared with CRSwNP disease alone. The relationship between these diseases in terms of shared immunological disbalance has been coined in the literature as "global airway disease" or "unified airway disease" and requires integrated treatment strategies. Our post hoc analysis of the Phase III randomised, double-blind, placebo-controlled, multicentre SYNAPSE study (GSK ID: 205687; NCT03085797) assessed the efficacy of mepolizumab, an anti-interleukin-5 monoclonal antibody, in simultaneously improving both CRSwNP and asthma outcomes versus placebo. By utilising a combined measure that accounts for quality of life, sinonasal symptoms and asthma control, we aimed to validate the potential of mepolizumab as an effective therapeutic option for global airway disease.

Authors

Institutions

Publication Details

Journal
Rhinology Journal
Published
2024-12-01
DOI
https://doi.org/10.4193/rhin24.337
Citations
4
Primary Topic
Sinusitis and nasal conditions
Type
article
Field-Weighted Citation Impact
2.32

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Global airway disease: mepolizumab simultaneously improves outcomes in severe CRSwNP and asthma

Jannis Constantinidis, Lingjiao Zhang, Peter W. Hellings, William G. Kerr et al.
4 citations
Rhinology Journal
Sinusitis and nasal conditions
2.32
article

Global airway disease: mepolizumab simultaneously improves outcomes in severe CRSwNP and asthma

Jannis Constantinidis, Lingjiao Zhang, Peter W. Hellings, William G. Kerr, Pallav L. Shah, Abraham L. Moure, Ibon Eguíluz‐Gracia, Joaquim Mullol, Vibeke Backer, R. Cuervo-Pinto
article en
4 citations

Abstract

Chronic rhinosinusitis with nasal polyps (CRSwNP) often co-exists with asthma and non-steroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD), creating a more severe phenotype and an additional burden compared with CRSwNP disease alone. The relationship between these diseases in terms of shared immunological disbalance has been coined in the literature as "global airway disease" or "unified airway disease" and requires integrated treatment strategies. Our post hoc analysis of the Phase III randomised, double-blind, placebo-controlled, multicentre SYNAPSE study (GSK ID: 205687; NCT03085797) assessed the efficacy of mepolizumab, an anti-interleukin-5 monoclonal antibody, in simultaneously improving both CRSwNP and asthma outcomes versus placebo. By utilising a combined measure that accounts for quality of life, sinonasal symptoms and asthma control, we aimed to validate the potential of mepolizumab as an effective therapeutic option for global airway disease.

Rhinology JournalVol. 0(0)
AHEPA University Hospital (GR), Orthopedic Specialty Hospital (US), Rigshospitalet (DK), Cancer Research And Biostatistics (US), Hospital Regional Universitario de Málaga (ES), Hospital Clínic de Barcelona (ES), Health Data Research UK (GB), MSD (Spain) (ES), Catholic University of America (US)
Eli Lilly and Company, AstraZeneca, Sanofi, Regeneron Pharmaceuticals, Glenmark Pharmaceuticals, Genentech, UCB Pharma
Good health and well-being
Openalex Percentile: Top 11%
Sinusitis and nasal conditions
2.32
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.